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Background: Global health institutions have called for governments, international organisations and health
practitioners to employ a human rights-based approach to infectious diseases. The motivation for a human rights
approach is clear: poverty and inequality create conditions for infectious diseases to thrive, and the diseases, in turn,
interact with social-ecological systems to promulgate poverty, inequity and indignity. Governments and
intergovernmental organisations should be concerned with the control and elimination of these diseases, as
widespread infections delay economic growth and contribute to higher healthcare costs and slower processes
for realising universal human rights. These social determinants and economic outcomes associated with
infectious diseases should interest multinational companies, partly because they have bearing on corporate
productivity and, increasingly, because new global norms impose on companies a responsibility to respect
human rights, including the right to health.
Methods: We reviewed historical and recent developments at the interface of infectious diseases, human
rights and multinational corporations. Our investigation was supplemented with field-level insights at corporate
capital projects that were developed in areas of high endemicity of infectious diseases, which embraced
rights-based disease control strategies.
Results: Experience and literature provide a longstanding business case and an emerging social responsibility
case for corporations to apply a human rights approach to health programmes at global operations. Indeed,
in an increasingly globalised and interconnected world, multinational corporations have an interest, and an
important role to play, in advancing rights-based control strategies for infectious diseases.
Conclusions: There are new opportunities for governments and international health agencies to enlist
corporate business actors in disease control and elimination strategies. Guidance offered by the United Nations
in 2011 that is widely embraced by companies, governments and civil society provides a roadmap for
engaging business enterprises in rights-based disease management strategies to mitigate disease transmission
rates and improve human welfare outcomes.
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Background
Infectious diseases have been closely linked with business
interests throughout history. The spread of infectious dis-
eases along trade routes facilitated the proliferation of
plague in Europe in the 1300s and various other epidemics
in the ensuing centuries, disrupting social interactions and
commerce [1]. With the industrialisation of the shipping
industry at the turn of the 20th century, jobs, communica-
tion, wealth, goods and infectious diseases spread through
ports with renewed force [2,3]. Trade through New York
City’s port brought in more than half of the national
federal budget, but it also brought typhus, yellow fever
and cholera epidemics to the United States of America in
the 1890s [4]. Through the port, the economy grew, while
infectious diseases spread through slums and immigrant
enclaves, striking the poor hardest with harsh, socially and
economically debilitating quarantines [4]. Then – as now
– the plight of those affected by disease was not merely
physical ill-health, but the social, economic, political and
environmental disempowerment that did – and still today
does accompany illness.
A cadre of modern-day “infectious diseases of poverty”
has been identified, which primarily persist in low-income
and middle-income countries, where foreign investment is
growing the fastest. They include the infectious diseases
mentioned above, as well as malaria, tuberculosis, HIV/
AIDS and many other vector-borne, bacterial, helminthic
and viral diseases [5,6]. High rates of infectious disease
and polyparisitism are well documented as both an indica-
tor and a promulgator of poverty. Although the wealthy
can also be affected by them, these diseases thrive in con-
ditions of scarcity – of food, shelter, clean water, improved
sanitation, income and education – and trap populations
in continued, entrenched poverty [7-9]. In many cases, this
entrenchment is compounded by corruption and failures
of governance. Companies can be complicit in the spread
of these diseases, but they can also be powerful players in
controlling them.
Infectious diseases and human rights
A governance framework
Infectious diseases can be understood through a human
rights framework, when the framework is properly and
effectively applied. The economic dimensions of disease,
associated with conditions of scarcity mentioned above,
alongside social-ecological systems, are analysed in human
rights terms under the umbrella of economic, social and
cultural rights. Meanwhile, the institutional dimensions of
disease spread, such as corruption, health system failures,political weakness and institutional ineptitude, colonise
the space of civil and political rights [10]. The human
rights framework is intended to strengthen the relation-
ship between human health and human dignity, as experi-
enced through protections and entitlements, codified in
international declarations and instruments.
These instruments – referred to collectively as the
International Bill of Human Rights – also depend upon
“duty bearers” meeting their allocated responsibilities
[11]. Duty bearers are entities charged with ensuring
that all rightsholders enjoy these rights. In this capacity
they try to remediate the conditions that result in the
entrenched, vicious cycle of diseases and poverty from
which rightsholders suffer.
The power to spread infectious diseases where they
are prevalent, and the power to prevent them, is held
by the bodies controlling socioeconomic, environmental
and political contexts: governments, intergovernmental
organisations and business enterprises. Governments have
historically been designated primary duty bearers, though
they have not always succeeded in fulfilling their duties
[12,13]. Recognising that some states lack the capacity –
or will – to fulfil the right to health, the International Bill
of Human Rights accords an additional responsibility to
other state parties, through “international assistance and
co-operation” where a need is demonstrated [11,14,15].
The role of business enterprises has not, historically, been
so clearly stated.
In 2011, the United Nations (UN) Human Rights Council
unanimously endorsed Guiding Principles on Business and
Human Rights (Guiding Principles in short). The Guiding
Principles call upon companies to “respect” human rights
[16]. This is not a new responsibility; “every organ of soci-
ety” has been called upon to “promote respect” for human
rights since 1948 [17]. However, it is a new and concrete ar-
ticulation, clarifying for corporate actors the meaning of
“respect” within the scope of their operations. Although hu-
man rights language is relatively new to companies, it has
gained traction. Roughly half of the world’s largest public
multinational corporations have embraced some dimension
of human rights responsibility, many in response to the
Guiding Principles. The major petroleum and mining asso-
ciations have developed human rights stances supporting
the Guiding Principles, and the Food and Agriculture
Organization (FAO) has made the language of the Guiding
Principles central to good practice on agriculture projects
[18-20]. The corporate acceptance of human rights
responsibilities is on the rise, documented through the
proliferation of human rights policies and the growing
demand for human rights reporting [21]. A step in fulfill-
ing the responsibility to respect human rights is the
conduct of “human rights due diligence,” which ensures
that companies know how their operations may affect the
lives of their workforce and surrounding communities,
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economic shifts, political affiliations and labour rights. The
designated scope of corporate responsibility with regard to
diseases is markedly more limited than that of government,
formally restricted only to areas where companies have im-
pacts. Yet the actions of companies should not be isolated
from the initiatives of global public health practitioners,
and in practice companies often do far more than host
states with regard to public health [22,23].
This paper proposes a method for broadening multi-
national corporations’ efforts to control, monitor and
eliminate infectious diseases where they affect societies
and businesses, using the Guiding Principles human
rights framework. First, it presents the relationship be-
tween human rights and infectious diseases of poverty.
Next, it examines corporations as human rights “duty
bearers” where they operate, identifying the potential im-
pacts they have on the spread of disease and the various
ways infectious diseases affect their business interests.
As an outlook, our piece proposes an approach for in-
tegrating business enterprises into ongoing initiatives
for preventing, controlling, monitoring and eliminating
infectious diseases, using systems-based approaches
that holistically examine the conditions that promote
disease spread. This approach benefits from the backing
of the business community’s support of the UN Guiding
Principles [16].
An analytical framework
Outside of the corporate realm, health practitioners have
struggled to convert the aspirational ideals of human
rights into actionable tools and outcomes [24]. Instead,
the human rights failings of states have acted as barriers
to interventions. Good governance – codified in human
rights instruments as the “right to public participation” –
and access to affordable, quality, culturally appropriate
healthcare – codified as the “right to health” – are vital for
many successful disease control interventions. “Security of
person”, meaning freedom from violence, and an informed
and engaged public (which is achieved by educating citi-
zens in line with the “right to education”) help empower
people to seek treatment, or at the very least to attend
school where treatment is often provided. Sometimes en-
vironmental conditions must be targeted where disease
vectors persist, in order to reduce reinfection (as for on-
chocerciasis control activities in Africa) [25,26]. These en-
vironmental interventions are a process of promoting the
“right to a clean and hygienic environment.” However, a
mixture of factors including budgetary limitations, inepti-
tude or state-driven conflict can create a milieu in which
the achievement of both human rights protections and
positive human health outcomes is inhibited. Health prac-
titioners are rarely positioned to unilaterally affect change
in these arenas.Multi-pronged, integrated, intersectoral programmes have
generated palpable public health gains in several interven-
tions, as for integrated management of childhood illness
(IMCI) [27,28]. Where integrated health programmes have
been augmented with the human rights framework, add-
itional value may be added. For example, the establishment
of technical guidance on human rights-based approaches to
maternal and child care has enabled health practitioners to
address systemic governmental and international failures that
lead to negative human rights outcomes, while also identify-
ing structural conditions that disempower women, politically,
socially and economically [29].
Figure 1 connects socioeconomic, cultural and political
conditions to the relevant human rights affected, demon-
strating the intimate connections between both the hu-
man rights and health outcomes resulting from external
forces. The column labelled “Outcomes of ill-health” is
drawn directly from the World Health Organization
(WHO) technical guidance and supplemented with a key
consideration recognised in the literature on neglected
tropical diseases: corruption and governance failures [6].
The column labelled “Relevant human rights affected” was
constructed through a Delphi method, deriving rights
from the International Bill of Human Rights [11].
Infectious diseases are a measurable outcome of, and a
contributor to, a wide variety of unrealised and unprotected
human rights, as visualised in Figure 1 and thoroughly
reported elsewhere. Illness affects social engagement (“right
to public participation”), academic performance (“right to
education”) [30-32], long-term earning power (“right to an
adequate standard of living”) [12,33,34] and, for HIV and
other highly stigmatising diseases, personal safety (“the right
to security of person”) [35-37].
Additionally, negative human rights conditions perpetu-
ate infectious disease spread through failures of governance
[38,39]. Government corruption can reduce available re-
sources for public health initiatives. Widespread graft can
press international donors to withdraw aid, further reducing
resources for achieving the highest attainable standard of
health for citizens. Where logistics, corruption and supply
chain management result in socioeconomic disparities in
coverage, the right to public participation is violated along-
side the right to health, even if the inequitable distribution
of coverage is inadvertent [40]. The “right to public partici-
pation and equal access to public service” can be violated
by the syphoning of funds from public coffers. In conflict
settings, governments can contribute to conditions of inse-
curity, militarising transportation routes or limiting access
to treatment for certain sub-populations. The role of state
security forces as they interact with existing social fissures
and resource disparities can make access to treatment
impossible, as has been the case in Nigeria, South Sudan,
Democratic Republic of the Congo and, most recently,
Syria [12,13,41,42].
Figure 1 Linkages between determinants of health and human rights affected by infectious diseases of poverty.
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eases have compounding effects. For example, an infection
might weaken immune responses and lower nutritive
intake, resulting in higher morbidity from a variety of
communicable and non-communicable diseases (NCDs)
[43]. Affected sub-populations have lower access to health
knowledge, treatment and services, which heightens the
risk of co-infection with other infectious diseases of pov-
erty [44]. Furthermore, the spread of infectious diseases is
multiplicative as transmission rates rise [45,46].
Methods
Ethical clearance was sought from the ethics commission
of Basel Stadt, where the Swiss Tropical and Public Health
Institute is located (Ethikkommission beider Basel refer-
ence number 304/13), as well as the National Research
Council of Malawi, via the National Health Sciences
Research Committee (NHSRC Reference number 1215).
Past efforts and present duties: multinational
corporations as duty bearers
The role of companies, in terms of both health concerns and
human rights concerns, differs from that of global health
agencies in obvious and crucial ways. For health agencies,
the promotion of global health is central to their mission,
and human rights is an advocacy argument, remindingparties of their commitments to strive for the highest attain-
able standards of care for all individuals, regardless of race,
gender, religion, socioeconomic status or other marginalising
characteristic [47]. For businesses, health and human rights
have had an evolving role in decision-making, and neither
is usually considered central to business operations. As
such, a clear delineation of the corporate duty to respect
human rights is useful in a discussion of corporate in-
volvement combatting infectious diseases.
Companies have been investing in infectious disease inter-
ventions for centuries, because the productivity gains associ-
ated with reducing transmission proximal to where they
were operating outweighed the cost of control measures.
However, the cost analysis has not always worked out to
favour human rights. In one of the United States of America’s
greatest industrial health disasters, employers of the Gauley
Bridge construction site exposed thousands of workers to
silica dust, resulting in over 1,500 deaths from silicosis, pneu-
monia and tuberculosis, none of which the implementing
company, Rinehart & Denis, or its contracting company,
Union Carbide, prevented or treated [48].
Past efforts: the business case
Laggards like Rinehart & Dennis persist today but they are
not the focus of this paper, because they are not the com-
panies that set trends for the future. Instead, we are
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aiming to do better. Some are acting in so-called enlight-
ened self-interest, finding a profit motive for doing good.
Others state an intention to explicitly benefit public
welfare through their operations. Corporate motives are
difficult to identify, but the outcomes of their actions can
be evaluated to establish best practices for the future. This
is important, as the globalisation of business is on the rise.
With roughly 80,000 multinational corporations
averaging 10 foreign affiliates, multinational compan-
ies generate approximately 11% of global gross domes-
tic product (GDP) [49]. Today’s corporate impacts on
global systems are historically unprecedented, associated
with large-scale agriculture, land clearance, urban expan-
sion and industrialisation [50]. Companies developing
infrastructure-intensive operations where infectious dis-
eases are widespread can exacerbate transmission simply
through their core business operations – building dams
and transportation corridors, hiring and moving around
construction teams, housing workers and other activities.
Yet, the public health challenges companies face, and the
remedies they pursue in the process of global expansion,
have a long history.
Corporate actors operating in the tropics were early
contributors to public health, spending millions in recog-
nition that a healthy workforce was a productive one.
Multinational mining, engineering and agribusiness firms
instituted environmental management programmes to
control malaria, yellow fever and other infectious diseases
near their operations throughout the early 1900s,
sometimes decades before government public health
programmes caught up in Latin America, the Middle
East, Asia and Africa [51-53]. In one example, Firestone
Plantations Company conducted extended surveys and
treatment of populations affected by human African tryp-
anosomiasis in Liberia during the 1940s. The company
collaborated with the WHO and the national government
in a mass-treatment programme to eliminate yaws be-
tween 1957 and 1959, simultaneous with a control
programme targeting smallpox, and assisted the WHO
to conduct a pulmonary tuberculosis survey in 1962.
With the biomedical surge of the 1960s, pharmaceut-
ical companies became partners with non-governmental
organisations (NGOs), governments and extractive in-
dustries to control and eliminate lymphatic filariasis,
onchocerciasis, trachoma, malaria and HIV/AIDS [53].
Some partners have profited from these interventions,
some have taken on significant expense and some may
have balanced the two [25,54-56]. Merck’s Mectizan Do-
nation Programme to treat and prevent onchocerciasis
may have fit each of these descriptions over its 27 years
of operation. Ivermectin was and is one of the firm’s
most profitable drugs, used on livestock and pets to
control heartworm. When Merck discovered its humanutility, it sought buyers but found none, so it offered to
donate the drug (under the name Mectizan) indefinitely
to any country that could not afford it. By 2004, the
programme had cost Merck over US$ 200 million, but
in exchange, the company received tax write-offs, posi-
tive press and the commitment of partner organisations
to prevent human-directed treatments from being ad-
ministered to animals, which would undermine veterin-
ary profits [57,58]. In another example, in managing
HIV/AIDS in sub-Saharan Africa, one mining company
estimated that at its peak, the epidemic would add 8-
17% to payroll costs, and another began training two to
three workers for a single job, assuming at least one
would die of AIDS [59]. To control the costs of lost
labour, and perhaps also to support public welfare, min-
ing companies intensified their investment in public
health, partnering with a variety of organisations to pro-
vide health personnel with strategic access to working
populations, and provide workers with access to treat-
ment [60]. Over time, these initiatives have broadened to
address comorbidities with tuberculosis and other ill-
nesses [61].
The collaborative approaches, across industries, aimed
at tackling various infectious diseases in tandem, have led
the way to increasingly holistic approaches to disease
control, accounting for the broader socioeconomic and
political conditions that affect projects and worker welfare.
Where such broader contexts have been ignored, results
have been mixed. As the Firestone Plantation Company
learned over decades in Liberia, public health is not the
only contextual concern that can affect productivity, nor
can public health be addressed strictly through health
interventions. Worker welfare proved itself to be more
comprehensive than the absence of illness as early as 1949
when Firestone workers first went on a wage strike. By the
time the company’s infectious disease programmes were
firmly established and the workforce (and dependents)
had achieved near universal health care access, workers
had begun recognising labour issues beyond the in-
adequate housing that fostered disease spread [62]. A 1963
strike of 20,000 Firestone workers shut down all 45 divi-
sions of the plantation’s operations. Workers demanded
higher wages, improved housing, shorter working hours
and better work conditions – essential human rights in a
context where wages were insufficient to buy rice, housing
had been unrepaired for decades and workdays reached
14 hours [63-65]. Labour disputes persisted until Liber-
ia’s civil war and beyond. In 2005 the company, by then
owned by Bridgestone, faced an Alien Tort Claims law-
suit filed by the workforce against Firestone’s use of
forced labour, child labour, cruel and unjust treatment
and negligent supervision creating an unsafe workplace
[66]. Also by then, a legal regime had been established in
Liberia to protect workers’ rights.
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cial, environmental and health impacts were initially spe-
cific and voluntarily negotiated. Many have become
generalised and gained the force of law. Since the 1970s,
through the passage of national environmental protec-
tion acts, companies have been required to mitigate their
impacts on the human and natural environment when
their activities are likely to cause harm [67]. Though in
early decades analysis of the “human environment” was
often minimised, both stakeholder pressure (particularly
on multi-lateral funding agencies such as the World
Bank’s private sector lending arm, the International
Finance Corporation, the Asian Development Bank and
the European Bank for Reconstruction and Develop-
ment) and overt legal challenges (in the United States of
America) gave a substantial boost to the field of health
impact assessment (HIA) in the 1990s, specifically to fill
the “health” gaps in environmental and social impact as-
sessments [68].
There are two main lessons to be drawn from
Firestone’s experience. First, corporate impacts on com-
munities affect corporate revenues. Land rights, labour
rights, civil rights and social and environmental impacts
of project development can increase a project proponent’s
risk of shutdowns and liabilities [69]. Second, addressing
those impacts requires holistic interventions, and a good
deed in one area of corporate activity does not cancel out
harm elsewhere.
Present duties: the human rights and social responsibility
case
Between 2008 and 2011, acknowledgement of corporate
impacts was further refined and rephrased in human
rights terms, reinforcing the role of companies as
“organs of society”, responsible for respecting human
rights in their activities [16]. Under unanimously
endorsed UN guidance, corporations are expected to
identify, prevent and remediate their human rights
impacts while they pursue their core business activities.
The direct effect of corporate activities on transmission
of infectious diseases makes it a corporate concern,
because a failure to reverse those effects represents a
lack of “respect” for the right to health and a number of
accompanying rights affected by infection. This poses
challenges for companies, but also presents an oppor-
tunity for them to adopt more effective disease manage-
ment strategies and benefit from collaborations with
international health agencies and national Ministries of
Health (MoH). Governments and intergovernmental
organisations can contribute to corporate programmes
and benefit from them; the successes companies achieve
within their walls or fence lines can be imparted and
scaled up by governments through effective knowledge
exchange and communication.These are ideological underpinnings of the Guiding
Principles, which are the current, de facto authority on
corporate interactions with rightsholders worldwide
[16]. Indeed, the Guiding Principles call on companies
to respect human rights by ensuring that their opera-
tions do not violate or contribute to violations of human
rights. Corporate responsibilities are also derived from
the International Covenant on Economic, Social and
Cultural Rights, which calls on the international com-
munity to provide technical and financial support to
governments attempting to fulfil rights but lacking re-
sources (Article 2).
The corporate impetus to holistically manage infec-
tious diseases now has three drivers: (i) an impact pre-
vention and remediation (or “do no harm”) principle
derived from human rights responsibilities; (ii) a growing
normative and legal framework; and (ii) a longstanding
business case for reducing absenteeism. Companies are
included in the category of international actors who are
to avoid violating rights and operate in accordance with
the standards of governments that attempt to protect
and promote them [29,70,71]. What that means in prac-
tice is largely procedural: companies need to understand
baseline conditions, evaluate impacts and take actions to
mitigate impacts (Figure 2). Processes for evaluating hu-
man rights impacts are increasingly well-developed and
in many ways linked to HIA processes [72]. Corporate
activities inadvertently affect the spread of many infec-
tious diseases, through the engineering of water storage
mechanisms, the consolidation of populations in cen-
tralised areas, and the introduction of hazards that
interact with infectious diseases. Dams disrupt hydrol-
ogy and water-filtration processes, facilitating the
spread of water-borne bacterial and parasitic diseases
[73]. The assembly of construction teams and other
labour forces into densely populated communities or
high-capacity dormitories increases risks of commu-
nicable disease transmission [74]. Where workers re-
locate to a job site, they may bring endemic diseases from
their home villages [50,75]. Worksite lifestyles may in-
crease disease spread upon workers’ return to their com-
munities during leave, including sexually transmitted
diseases, yellow fever and tuberculosis [50,76].
Corporate projects that require the resettlement of
populations living atop or adjacent to project sites have
myriad and complex human rights impacts. Social dis-
location can affect security of person and the rights of
children. The stress of relocation often results in in-
creased infectious disease rates, decreased educational
performance by resettled children and a loss of liveli-
hood and income as families rebuild their homes, fields
and business ties. The introduction of toxins, toxicants
and particulates into air is another major contributor of
corporate activity to negatively impact infectious disease
Figure 2 Key players affecting human rights outcomes through infectious disease management, and their respective roles.
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Gauley Bridge incident mentioned above, the problem-
atic occupational exposure history of South African
mine workers to silicosis, as it fomented a national tu-
berculosis crisis, typifies such negative corporate human
rights impacts [80].
Even the direct positive impacts of a project can result
in negative health and human rights outcomes that re-
quire remediation under the “do no harm” principle. For
instance, the improvement in size and reliability of food
supplies, often facilitated by mechanised farming or
wage labour, enables increased human and livestock
population density, which increases animal-to-human
and human-to-human transmission risks of infections.
Likewise, as large-scale industry increases service deliv-
ery and access to a money economy to previously iso-
lated subsistence communities, environmental impacts
and economic transitions have effects on the rights to a
clean environment, food, health, adequate standard of
living and, for children, the right to a family life.
Mechanised farming may also promote the transition to
non-food crops which, on the one hand may improve ac-
cess to markets and farming inputs, and on the other
may affect water supply, deforestation and, over years,
result in declining yields, reduced standards of living
and increased presence of disease vectors [81-84].
In conflict settings, core business activities can indir-
ectly affect disease spread, through processes and proce-
dures that directly affect human rights. This is most
apparent in situations where companies develop projects
in conflict or post-conflict zones, in which even securingthe project periphery can increase public insecurity, to
the detriment of community welfare. One of the most
thoroughly documented cases of this is the militarisation
of Ogoniland in south eastern Nigeria to secure territor-
ies for Royal Dutch Shell’s oilfields. The company’s
pipelines have experienced numerous breaches since op-
erations began in 1958, resulting in degradation of farm-
lands and fishing grounds, which has affected nutrition
in the area. Additionally, the ethnic minority Ogoni who
have protested the environmental harms have been
violently suppressed by ethnic majority troops from
southern Nigeria. Shell’s own security personnel have
not been directly linked to violence, but Shell imported
weapons for the Nigerian military [85,86]. The insecurity
and dislocation have had wide-reaching public health ef-
fects [87]. In another example, corporate security forces
protecting mines in Sierra Leone contributed to atroci-
ties during the civil war. The violence has been tied to
myriad lingering negative health impacts [88].Results and Discussion: implications on the
ground
Limitations of a human rights framework without
enforcement capabilities
A human rights approach to operating in conflict set-
tings has nominally been applied by many extractive
companies, through their participation on the Voluntary
Principles on Security and Human Rights. This mechan-
ism has embodied two of the major drawbacks of the
human rights framework, namely (i) that it is voluntary
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of others.
Without express, contractual or legal advances, the
human rights regime is seen by some as “toothless” [89].
Companies are not well acquainted with the human
rights framework and, with little guidance, many have
ignored it. Stiglitz and others refer to this current system
as “global governance without global government” [90,91],
whereby a framework exists for sharing duties, but no
implementing agency can ensure that each duty bearer
plays its part. Companies in the past have tended to pick
and choose among the rights they deem relevant [92].
However, cherry-picking rights poses risks. The con-
fluence of human rights duties and infectious disease
management is convenient but also complicated. Imple-
mented partially or improperly, the human rights ap-
proach can be ineffective, or at worst, counterproductive
[47]. One arena where the human rights approach has
garnered legitimate criticism in the public health (and
private business) sphere is in the HIV/AIDS pandemic.
For migrant workers seeking private sector jobs in
Oman, for example, a negative HIV test certificate is re-
quired for entry, to the detriment of the right to privacy,
work, non-discrimination and security of person [93].
Conversely, the public health sector’s focus on reversing
stigma and protecting privacy rights became a factor in
the global spread of HIV. Vital and exacting standards
for protecting the seropositive from stigma, discrimin-
ation and the psychologically damaging effects of a posi-
tive diagnosis of a then-untreatable disease did much to
protect vulnerable groups when medicine had little to
offer HIV/AIDS patients. However, as treatment im-
proved, destigmatisation progressed (though, notably,
not for all at-risk groups, such as homosexual males in
Africa), and the privacy standards remained, while the
human rights risks of not knowing one’s HIV status
began proliferating. HIV has converted into a complex
chronic illness requiring comprehensive long-term man-
agement, but management is hindered by the very priv-
acy standards that offered the seropositive their greatest
initial protection [94]. In sub-Saharan Africa, the result
has been sweeping impacts on socioeconomic rights for
families impoverished by illness and fragmented by
death [95,96].
A narrow focus on a single rightsholder group has
been similarly problematic. Perhaps the most historically
powerful example of this is embodied in the “environmen-
tal justice” movement in the United States of America,
which chronicled the systematic disregard for the health
of minority populations living in proximity to industrial
sites at the same time that occupational health and safety
regulations were ensuring that (non-minority) employees
were better protected from those same hazards [97,98].
The result of this racially-based disregard was a series oflawsuits culminating in a legal movement and a (far from
complete or perfect) new global sensitivity. It is because
the human rights lens takes the long- and short-term, dir-
ect and indirect, and single and cumulative impacts into
consideration that it offers value. Neglect of either particu-
lar rights or particular rightsholders poses problems. As
such, the full suite of rights and rightsholders should be
considered systematically.
Blending corporate “do no harm” with state “duty to
protect”: the state role in the guiding principles
Just as the human rights framework weakens when im-
plemented for particular rights or rightsholders, it also
loses effectiveness when implemented to exclude certain
duty bearers. Again, the Guiding Principles provide dir-
ection to integrate inter-governmental organisations,
government bodies and business enterprises in the pro-
tection of human rights, systematically and holistically.
They lay out a system of global governance incorporat-
ing the roles of governments, international financial in-
stitutions, civil society and corporations to create a
network of responsible parties with interacting but not
overlapping duties. Examples above generally present
states as useful partners with limited means, or as barriers
to change. They can do more. Fox and Meier (2009) have
proposed that states could pass laws codifying the duties
of international financial players to include respect for hu-
man rights [99]. The Guiding Principles, too, instruct
states to “consider the full range of permissible preventa-
tive and remedial measures, including policies, legislation,
regulations and adjudication” [16]. Within the scope of
direct foreign investment, some states have already begun
doing this. In 2013 the Government of Honduras signed a
Memorandum of Understanding (MoU) with BG Inter-
national, a hydrocarbon exploration and extraction com-
pany, incorporating respect for human rights as a core
commitment of the partnership. The MoU was published,
temporarily, through the Extractive Industries Transpar-
ency Initiative (EITI), potentially providing guidance for
other states and extractive companies.
To be fully effective, such laws, contracts and regula-
tions should conform to the criteria for “respect” that in-
clude the active duty of investigating impacts. First,
companies should have a policy detailing their position
on human rights for all rightsholders affected by opera-
tions, including workers and neighbouring communities.
Second, they should develop “human rights due dili-
gence” processes, documenting the steps they have taken
to ensure that their activities do not violate or contribute
to the violation of human rights. Finally, they should
develop mechanisms, complementary to those of states,
to ensure that victims of rights violations have access
to remedy. By requiring these actions of companies,
and evaluating the outputs produced by companies,
Salcito et al. Infectious Diseases of Poverty 2014, 3:39 Page 9 of 13
http://www.idpjournal.com/content/3/1/39governments can increase their understanding of corporate
impacts, understand the epidemiological implications, and
collaborate with companies to find solutions [16].
The comprehensive human rights approach has advan-
tages over direct approaches to health, or even the right
to health, as past efforts to target health directly have
been limited by the assumption that health belongs
within the scope of medicine, subject to the budget limi-
tations of the MoH [99]. A human rights approach,
which incorporates the full suite of rights, recognises the
interrelationship between health and social determinants
of health, requiring parties to address the non-linear
relationships between impacts and outcomes. Private
sector health and infectious diseases initiatives deserve
praise for their successes [23,100], but cautionary
tales from rights-neglectful initiatives like Firestone’s
should help steer companies towards holistic and
rights-respectful approaches.
A role for international organisations within the guiding
principles
The Guiding Principles also call for greater policy coher-
ence at the international level, setting out a role for
intergovernmental institutions that aligns with the hu-
man rights obligations of their member states. For the
WHO, international financial institutions and trade asso-
ciations, these obligations are the foundational human
rights instruments, to which all or most states are mem-
bers. The strong and broad support that the Guiding
Principles enjoy empower policymakers to implement
their recommendations, including adopting processes to
ensure that corporate activities “respect” human rights
and intergovernmental institutions find smart ways to
collaborate with companies that are already on the
ground in areas to address endemic diseases simultan-
eously with longstanding poverty.
Delving deeper into “human rights due diligence,”
companies are expected to carry out ex ante and on-
going assessments of their impacts on rightsholders.
MoH, in collaboration with the WHO, the Global
Fund to Fight AIDS, Tuberculosis and Malaria, the
Centers for Disease Control and Prevention (CDC)
and other health agencies keep records of epidemics,
incidence rates and prevalence rates, which comprises
baseline conditions for companies investing in new
projects in these locations. These data might be of low
quality or reliability, but they can allow skilled and ex-
perienced assessors to make qualitative conclusions
about risks. Leading companies are already commis-
sioning human rights impact assessments (HRIA),
which – when they are done properly – analyse such
data. At a Uranium mine in northern Malawi owned
by an Australian company, Paladin Energy, the initial
paucity of local data prompted the company to begintracking HIV testing, treatment and counselling and
bolstering the Malawian government’s statistics.
ExxonMobil is currently running a much broader in-
fectious disease monitoring programme at its opera-
tions in Papua New Guinea, using improved national
data to track changes in the project area and to design
interventions. Such alliances can be costly in some
cases but have proven effective [22,101]. Although
ExxonMobil is not currently using its health findings
to inform its human rights approach, Paladin is. The
tracking Paladin conducted at its Malawi mine enabled
the company to benchmark access to treatment in the
project compared to the rest of the nation. The most
recent human rights monitoring report revealed that
Paladin’s programmes insulated local communities from
a national antiretroviral treatment stock-out, positively
impacting the right to health while the government was
unable to fulfil its duty. A dynamic and iterative approach
to understanding the causes and outcomes of health inter-
ventions will enable all duty bearers to tailor interventions
to local conditions.
Conclusions
The impacts of infrastructure projects differ across re-
gions, contexts and industries [102-104]. For this reason,
the human rights approach considers the direct and in-
direct interactions between a corporate project and its
operating context. This holistic understanding not only
enables companies to identify and manage risks, but to
maximise positive impacts.
Vertical, disease-specific interventions do not suffice
to protect business interests or human rights, partly be-
cause they cannot pre-emptively disrupt the cycle of dis-
ease and poverty that characterises infectious diseases
[105]. A human rights approach examines the full suite
of interconnected rights as it applies to the full range of
rightsholders and duty bearers. The human rights lens
identifies the risks and their associated appropriate remedi-
ation measures as well as the sweeping positive impacts
that must also be considered in project development. Major
petroleum companies have recognised the value of compre-
hensive, holistic interventions.
The very clear relationship between occupational ill-
nesses, chronic diseases and infectious diseases necessi-
tate that they be tackled together through a holistic
approach [106,107]. Zoonotic diseases, too, rest under
this umbrella, with the OneHealth strategy already pre-
senting a model for integrating the economic, social and
health drivers and outcomes of holistic interventions
[108]. Although this paper focuses on infectious dis-
eases, leading health initiatives have already begun
expanding the health lens to include NCDs and chronic
illnesses that can result as much from the benefits and
risks of globalisation [109,110]. There is a growing
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ability of processed foods and beverages at locations
where globalised business changes local diets is affecting
coronary heart disease rates, diabetes myelitis and com-
plications of obesity [111].
Fortunately, many corporate impacts are inherently
positive and promote a “virtuous cycle”. Improving edu-
cation, nutrition, knowledge and empowerment creates
positive feedback loops that can neutralise or reverse the
cycle of illness and disempowerment that are character-
istic for infectious diseases of poverty. These inputs are
credited with much of the improvement in public health
and life expectancy in Europe since the end of World
War II [112,113]. In our interconnected world, research
priorities are shared across industries and disciplinary
fields [114]. In part because corporate investment in
communities often includes contributions to education,
nutrition, equality and access to information, some com-
panies have seen striking success in their public health
interventions. In the Amazon, forest clearance is corre-
lated to elevated malaria incidence, with the exception
of corporate-sponsored clearance programmes, which al-
locate resources to environmental controls and public
education campaigns [115]. This is a positive indication
of the corporate cognisance of systems-thinking – in-
corporating preventive measures into activities that
would otherwise pose health risks [44]. Leading compan-
ies educate communities and supply insecticide-treated
nets, control vegetation and drain swamplands to reduce
transmission of mosquito-borne infections and success-
fully manage schistosomiasis and other infectious dis-
eases. In the course of a HRIA between 2008 and 2013,
Paladin Energy identified gaps in the Government of
Malawi’s HIV/AIDS prevention programme to identify
treatment and control failures in their project area and
fill the gap through collaborative efforts with the MoH
and a variety of civil society groups [72,116].
Through the Guiding Principles, policymakers have
new tools to benefit from the presence of private sector
actors in rural and resource-constrained settings, as well
as a duty to ensure that these actors recognise their im-
pacts and manage them. Systematising interventions,
and integrating them into ex ante analyses and monitor-
ing programmes at corporate project sites, including
mines, dams, oilfields, plantations and manufacturing
sites, can better protect the public health of communi-
ties and to manage financial risks to companies. Infec-
tious diseases should be tackled together [117]. They
include most zoonotic diseases that affect livelihoods
and economic growth in the framework of human and
animal health [118]. OneHealth interventions broaden
the lens of human illness to recognise complex systemic
interactions [108,119]. Furthermore, infectious diseases
considered in this analysis are one aspect in the broadercontext of health problems, which include environmen-
tal determinants and risk factors for NCDs. The lens for
examining these complex interactions should be refined
to enable consideration of the role of human rights. The
human rights approach is naturally conducive to holistic
analysis, and it also brings together the various duty
bearers and acknowledges the diverse rightsholders af-
fected. Corporate risk matters – projects are expensive
in low-income countries, and this is where infectious
diseases of poverty have their strongest hold. Companies
can ensure that they are preventing negative human
rights impacts while maximising workforce health and
efficiency by tackling these diseases within the human
rights contexts where they proliferate.
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